HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hyperlipidaemia induced by a high-cholesterol diet leads to the deterioration of guanosine-3',5'-cyclic monophosphate/protein kinase G-dependent cardioprotection in rats.

AbstractBACKGROUND AND PURPOSE:
Hyperlipidaemia interferes with cardioprotective mechanisms, but the cause of this phenomenon is largely unknown, although hyperlipidaemia impairs the cardioprotective NO-cGMP system. However, it is not known if natriuretic peptide-cGMP-protein kinase G (PKG) signalling is affected by hyperlipidaemia. Therefore, we investigated the cardioprotective efficacy of cGMP-elevating agents in hearts from normal and hyperlipidaemic rats.
EXPERIMENTAL APPROACH:
Male Wistar rats were rendered hyperlipidaemic by feeding with 2% cholesterol-enriched chow for 12 weeks. Hearts isolated from normal and hyperlipidaemic rats were perfused (Langendorff mode) and subjected to 30 min occlusion of the left main coronary artery, followed by 120 min reperfusion. 8-Br-cGMP (CG, 10 nM), B-type natriuretic peptide-32 (BNP, 10 nM), S-nitroso-N-acetyl-penicillamine (SNAP, 1 microM) were perfused from 10 min prior to coronary occlusion until the 15th min of reperfusion. Infarct size (% of ischaemic risk zone) was determined by triphenyltetrazolium staining.
KEY RESULTS:
Treatment with CG, SNAP or BNP decreased infarct size significantly in normal hearts from its control value of 41.6 +/- 2.9% to 15.5 +/- 2.4%, 23.3 +/- 3.0% and 25.3 +/- 4.6%, respectively (P < 0.05). Protection by BNP was abolished by co-perfusion of PKG inhibitors KT5823 (600 nM) or Rp-8pCPT-PET-cGMPs (1 microM), confirming its PKG dependence. In hearts from hyperlipidaemic rats, CG, SNAP or BNP failed to decrease infarct size. Hyperlipidaemia did not alter basal myocardial PKG content, but decreased its activity as assessed by phosphorylation of cardiac troponin I.
CONCLUSIONS AND IMPLICATIONS:
This is the first demonstration that defects in the cardioprotective cGMP-PKG system could be a critical biochemical anomaly in hyperlipidaemia.
AuthorsZ Giricz, A Görbe, J Pipis, D S Burley, P Ferdinandy, G F Baxter
JournalBritish journal of pharmacology (Br J Pharmacol) Vol. 158 Issue 6 Pg. 1495-502 (Nov 2009) ISSN: 1476-5381 [Electronic] England
PMID19845676 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Cardiotonic Agents
  • Dietary Fats
  • Troponin I
  • Natriuretic Peptide, Brain
  • 8-bromocyclic GMP
  • S-Nitroso-N-Acetylpenicillamine
  • Cyclic GMP-Dependent Protein Kinases
  • Cyclic GMP
Topics
  • Animals
  • Cardiotonic Agents (pharmacology)
  • Cyclic GMP (analogs & derivatives, metabolism, pharmacology)
  • Cyclic GMP-Dependent Protein Kinases (metabolism)
  • Dietary Fats (toxicity)
  • Disease Models, Animal
  • Hyperlipidemias (complications, physiopathology)
  • Male
  • Myocardial Infarction (etiology, prevention & control)
  • Myocardial Reperfusion Injury (physiopathology, prevention & control)
  • Natriuretic Peptide, Brain (pharmacology)
  • Phosphorylation
  • Rats
  • Rats, Wistar
  • S-Nitroso-N-Acetylpenicillamine (pharmacology)
  • Troponin I (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: